Precision Biotics Market

The precision biotics market is estimated at USD 4.91 billion in 2026 and is projected to reach USD 9.26 billion by 2031, at a CAGR of 13.5% from 2026 to 2031. The precision probiotics market is experiencing strong growth, driven by increasing scientific understanding of the human microbiome and rising demand for personalized nutrition and preventive healthcare. Unlike conventional probiotics, precision probiotics are designed using individual microbiome profiles, genetic information, lifestyle factors, and disease-specific biomarkers to deliver targeted health benefits. Growing consumer awareness of gut microbiome health, coupled with advances in next-generation sequencing, metagenomics, and microbiome analytics, is accelerating the adoption of personalized probiotic solutions for digestive health, metabolic disorders, immune support, and women's health. Furthermore, increasing clinical evidence supporting strain-specific probiotic efficacy is encouraging healthcare professionals and consumers to adopt more targeted microbiome interventions.

The growth of the precision probiotics market is further supported by expanding investments in microbiome research, increasing collaborations between biotechnology companies, academic institutions, and healthcare providers, and the growing integration of microbiome-based diagnostics into clinical practice. The rising prevalence of chronic gastrointestinal diseases, obesity, diabetes, inflammatory bowel disease, and other microbiome-associated conditions is driving demand for individualized probiotic therapies. In addition, increasing consumer preference for evidence-based nutritional supplements and the emergence of direct-to-consumer microbiome testing services are enabling companies to develop customized probiotic formulations that align with individual health needs and improve therapeutic outcomes.

To know about the assumptions considered for the study download the pdf brochure

Recent technological advancements in artificial intelligence, machine learning, multi-omics analysis, whole-genome sequencing, and computational microbiome modeling have significantly enhanced the discovery, selection, and validation of precision probiotic strains. Manufacturers are increasingly focusing on next-generation probiotics, engineered microbial consortia, and data-driven formulation platforms to improve colonization efficiency, strain functionality, and clinical effectiveness. Additionally, continuous improvements in microbiome sequencing technologies, biomarker identification, and regulatory science are supporting the development of highly targeted microbiome therapeutics, helping companies optimize product innovation while addressing the growing demand for personalized, science-backed probiotic solutions.

The key player in the industry includes BioGaia (Sweden), Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd (Japan), Danone (France), KANEKA CORPORATION (Japan), Symrise (Germany), Jarrow Formulas, Inc (US), Pendulum (US), thegoodbug (India), Seed Health, Inc (US), and Infinant Health Inc (US). They are gaining traction by offering energy-efficient and customized solutions, particularly in the Asia Pacific region, thereby intensifying competition and supporting overall market expansion.

Novonesis Group (Denmark)

Novonesis Group is a global biosolutions leader established in 2024 through the merger of Novozymes and Chr. Hansen. It offers clinically validated probiotic strains, microbiome solutions, and precision biotics for digestive, immune, metabolic, women's, and infant health. The company combines extensive microbial expertise, advanced strain discovery capabilities, and one of the world's largest microbial collections to develop science-backed microbiome solutions. Its position in the precision probiotics market was further strengthened through Novozymes' acquisition of PrecisionBiotics Group in 2020, which expanded its human health portfolio and enhanced its capabilities in personalized microbiome and precision biotic solutions.

Procter & Gamble (US)

Procter & Gamble (P&G) participates in the precision probiotics market through its Align brand, offering clinically researched, strain-specific probiotic formulations designed to support digestive health and gut microbiome balance. Leveraging its extensive consumer healthcare expertise, scientific research, and global brand presence, P&G has established Align as a leading premium probiotic brand, providing targeted digestive wellness solutions and strengthening its position in the growing precision microbiome-based health market.

Unilever (UK)

Unilever participates in the precision biotics market through its wellness brand OLLY, which offers science-backed digestive health and microbiome support supplements. Leveraging Unilever's global presence in health and wellbeing, OLLY delivers targeted wellness formulations in convenient consumer-friendly formats, strengthening the company's position in the growing precision biotics market by addressing increasing demand for personalized gut health solutions.

Market Ranking

The precision biotic market is characterized by a moderately consolidated structure, with a mix of leading global manufacturers and numerous regional suppliers competing across various end-use segments. Major companies, including Novonesis Group (Denmark), Procter & Gamble (US), Unilever (UK), dsm-firmenich (Switzerland), Metagenics, LLC (US), Yakult Honsha Co., Ltd (Japan), Danone (France), KANEKA CORPORATION (Japan), and Symrise (Germany)-(Probi), maintain strong market positions through their extensive manufacturing capabilities, global distribution networks, advanced research expertise, and diversified product portfolios.

Novonesis Group is a leading player in the global precision biotics market, providing a broad portfolio of clinically documented probiotic strains, precision probiotics, synbiotics, postbiotics, and microbiome-based solutions for the human health, food and beverage, and dietary supplement industries. The company serves applications across digestive health, immune health, metabolic wellness, women's health, and infant nutrition. Leveraging one of the world's largest microbial collections, advanced strain discovery capabilities, and a strong global manufacturing and distribution network, Novonesis enables customers to develop science-backed, high-quality precision biotic products while meeting stringent regulatory and clinical standards.

The precision biotics market is witnessing rapid evolution, driven by increasing demand for personalized nutrition, microbiome-based healthcare, and clinically validated wellness solutions. Manufacturers are focusing on developing strain-specific probiotics, synbiotics, postbiotics, and next-generation biotics using advanced microbiome sequencing, artificial intelligence, and biomarker-based research to improve product efficacy and regulatory compliance. The market is also benefiting from expanding applications in digestive health, metabolic disorders, immune health, women's health, infant nutrition, and healthy aging, creating new growth opportunities for science-backed precision biotic solutions.

At the same time, small and mid-sized precision biotic producers continue to play an important role, particularly in regional markets. These companies offer flexible production capabilities, customized formulations, competitive pricing, and strong local customer support. While they may not possess the global scale and distribution networks of leading multinational players, they remain competitive by addressing niche application requirements and responding quickly to evolving customer demands.

Related Reports:

Precision Biotics Market by Type (Precision Probiotics, Next-generation Probiotics, Synbiotics, Postbiotics), End Use Industry, Health/Functional Positioning, Distribution Channel, and Region – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]